Zhejiang AngLiKang Pharmaceutical CO.,LTD. (SHE:002940)
China · Delayed Price · Currency is CNY 32.16
+0.34 (1.07%)
Feb 3, 2026, 3:04 PM CST
SHE:002940 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,447 | 1,513 | 1,621 | 1,560 | 1,375 | 1,285 |
Other Revenue | - | - | - | 8.09 | 5.48 | 4.17 |
| 1,447 | 1,513 | 1,621 | 1,568 | 1,380 | 1,290 | |
Revenue Growth (YoY) | -6.97% | -6.63% | 3.32% | 13.62% | 7.03% | -7.63% |
Cost of Revenue | 899.42 | 925.32 | 913.72 | 674.86 | 488.02 | 321.24 |
Gross Profit | 547.28 | 587.78 | 706.85 | 893.58 | 892.36 | 968.41 |
Selling, General & Admin | 267.93 | 274.01 | 396.04 | 631.65 | 671.11 | 745.48 |
Research & Development | 171.78 | 214.34 | 143.37 | 112.62 | 52.55 | 43.88 |
Other Operating Expenses | -4.7 | -18.66 | 5.33 | 8.56 | 14.8 | 14.26 |
Operating Expenses | 435.22 | 469.41 | 543.21 | 751.81 | 741.11 | 806.45 |
Operating Income | 112.06 | 118.37 | 163.64 | 141.77 | 151.25 | 161.96 |
Interest Expense | -13.22 | -16.6 | -14.17 | -6.39 | -0.37 | -0.17 |
Interest & Investment Income | 14.48 | 18.96 | 21.95 | 17.52 | 25.78 | 19.08 |
Currency Exchange Gain (Loss) | 7.21 | 7.21 | 2.44 | 1.27 | -0.58 | -0.33 |
Other Non Operating Income (Expenses) | -5.6 | -0.43 | -0.72 | -1.69 | -0.36 | -0.52 |
EBT Excluding Unusual Items | 114.93 | 127.51 | 173.13 | 152.48 | 175.72 | 180.01 |
Gain (Loss) on Sale of Investments | -14.02 | -5.69 | -1.7 | -2.96 | -9.05 | -3.53 |
Gain (Loss) on Sale of Assets | -0.09 | -0.01 | -0.04 | -0.39 | -0.59 | -0.08 |
Asset Writedown | -3.2 | -2.93 | -1.96 | -2.18 | - | -1.04 |
Other Unusual Items | 66.81 | 39.49 | 37.77 | - | 6.56 | 35.39 |
Pretax Income | 164.43 | 158.37 | 207.2 | 146.94 | 172.65 | 210.75 |
Income Tax Expense | 18.76 | 6.48 | 24.13 | 14.96 | 31.32 | 29.44 |
Earnings From Continuing Operations | 145.67 | 151.89 | 183.06 | 131.99 | 141.32 | 181.3 |
Minority Interest in Earnings | -37.58 | -71.56 | -44.69 | -4.69 | -21.48 | -17.58 |
Net Income | 108.09 | 80.33 | 138.37 | 127.3 | 119.84 | 163.72 |
Net Income to Common | 108.09 | 80.33 | 138.37 | 127.3 | 119.84 | 163.72 |
Net Income Growth | 37.67% | -41.94% | 8.70% | 6.22% | -26.80% | 45.83% |
Shares Outstanding (Basic) | 200 | 201 | 201 | 199 | 200 | 190 |
Shares Outstanding (Diluted) | 200 | 201 | 201 | 199 | 200 | 190 |
Shares Change (YoY) | 1.31% | 0.15% | 0.82% | -0.42% | 5.03% | 0.70% |
EPS (Basic) | 0.54 | 0.40 | 0.69 | 0.64 | 0.60 | 0.86 |
EPS (Diluted) | 0.54 | 0.40 | 0.69 | 0.64 | 0.60 | 0.86 |
EPS Growth | 35.89% | -42.03% | 7.81% | 6.67% | -30.30% | 44.81% |
Free Cash Flow | 144.95 | 159.14 | 151.96 | 115.92 | 110.33 | 107.65 |
Free Cash Flow Per Share | 0.72 | 0.79 | 0.76 | 0.58 | 0.55 | 0.57 |
Dividend Per Share | 0.225 | 0.125 | 0.210 | 0.207 | 0.143 | 0.238 |
Dividend Growth | 7.14% | -40.48% | 1.50% | 44.99% | -39.99% | -50.00% |
Gross Margin | 37.83% | 38.85% | 43.62% | 56.97% | 64.65% | 75.09% |
Operating Margin | 7.75% | 7.82% | 10.10% | 9.04% | 10.96% | 12.56% |
Profit Margin | 7.47% | 5.31% | 8.54% | 8.12% | 8.68% | 12.70% |
Free Cash Flow Margin | 10.02% | 10.52% | 9.38% | 7.39% | 7.99% | 8.35% |
EBITDA | 206.14 | 205.3 | 241.03 | 202.87 | 197.6 | 203.65 |
EBITDA Margin | 14.25% | 13.57% | 14.87% | 12.93% | 14.31% | 15.79% |
D&A For EBITDA | 94.08 | 86.93 | 77.39 | 61.1 | 46.36 | 41.69 |
EBIT | 112.06 | 118.37 | 163.64 | 141.77 | 151.25 | 161.96 |
EBIT Margin | 7.75% | 7.82% | 10.10% | 9.04% | 10.96% | 12.56% |
Effective Tax Rate | 11.41% | 4.09% | 11.65% | 10.18% | 18.14% | 13.97% |
Revenue as Reported | 1,471 | 1,538 | 1,626 | 1,568 | 1,380 | 1,290 |
Advertising Expenses | - | 146.29 | 251.93 | 526.87 | 585.69 | 672.14 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.